bonyf NV / Key word(s): Annual Results bonyf NV: bonyf’s 2023 financial statements made available 28-Jun-2024 / 17:12 CET/CEST
Dissemination of a Financial Wire News, transmitted by EQS Group. |
FDA Investigating ‘Serious Risk’ of Malignancy After CAR-T Therapy
The FDA has launched an investigation into reports of T-cell malignancies in patients treated with autologous chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation